Fibrinolysis inhibitors are of value in the control of severe overdosage with fibrinolytic agents. The discussion so far has been mainly on the use of fibrinolytic inhibitors to reduce or arrest local bleeding in the absence of an increase in systemic fibrinolytic activity. There are still other clinical applications of antifibrinolytic drugs that are worth mentioning, since furthei research in these areas may prove rewarding.
Hereditary and non-hereditary angioneurotic oedema
Hereditary angioneurotic oedema is an inborn defect in the synthesis of a serum 0x2-globulin which is primarily an inhibitor of the activation of C'ls subcomponent of the first component of complement.' In consequence the enzymatic activity of C'l-esterase is uncontrolled. The missing neuraminoglycoprotein is also capable of blocking the action of plasma kallikrein and PF/Dil, a plasma factor which increases cutaneous vascular permeability.2 C'1-inactivator is in addition a plasmin substrate.
The oedema of subcutaneous and submucous tissues ofhereditaryangioneurotic oedema is well controlled by synthetic inhibitors such as epsilon-aminocaproic acid or tranexamic acid. Since Cl inhibitor activity and C4 concentrations are not influenced by these drugs it has been suggested that they do not act on Cl but on some further step or that they may have to do with the release of a vasoactive kinin from the human second component of complement once it has been cleaved by Cl- 
Contraception by inhibition of acrosin
The acrosome, a cape-shaped organel at the head of spermatozoa, contains acrosin, a proteinase with trypsin-like specificity. Present evidence suggests that activation of the zymogen precursor occurs by several steps of sequential proteolytic cleavages and involves the splitting of an arginyl-X bond. The major role of this proteinase appears to be the digestion of a small oblique tunnel through the zona pellucida, a dense glycoprotein capsule surrounding the ovum, allowing the spermatozoon to enter the perivitelline space where fusion of the plasma membranes of the male and female gametes occurs.'3 Trypsin inhibitors will inhibit the dissolution of the zona pellucida.14 15 Acrosomal proteinase is specific for the peptide and ester bonds of lysine and arginine. The physicochemical, enzymatic, structural, and antigenic properties of acrosin are strikingly similar to those of pancreatic trypsin. There is a physiological relationship between this proteinase and proteinase inhibitois in the human seminal plasma, cervical mucus, and oviduct fluid.16 17 The function of the acrosin inhibitors in the male is mainly that of rapidly neutralising the enzymatic potential of acrosin whenever the enzyme is activated or liberated at the wrong place-that is, before mating or captivation of the spermatozoa in the female reproductive tract.
Verstraete
Tranexamic acid is known to diffuse into the prostate and seminal vesicles from where it is excreted into the semen. Epsilon-aminocaproic acid given to male rats results in a reversible 50% reduction in fertility. Tranexamic acid given to healthy men volunteers decreased the fibrinolytic activity of the semen but did not change the in-vitro sperm migration in cervical mucus collected at the time of ovulation. '8 Prevention of lysis of exogenous fibrin Neurosurgeons are experimenting with fibrin sutures for peripheral nerves. They use human fibrinogen (5 to 10 %) which is clotted on the spot with thrombin. Addition of inhibitors of fibrinolysis, either locally or systemically, prevents the early lysis of the fibrin sutures.'9 The same technique can be used for fixing fascia transplants-for example, in operations in the ear where suturing is difficult or impossible. Graft survival for more than six months and improved hearing resulted in 31 cases of myringoplasty when clotted fibrinogen was used under cover of tranexamic acid compared with 30 similar operations without fibrin suture. 20 Lyophilised fibrinogen has been used to close vesicovaginal fistulae after gynaecological procedures such as hysterectomy or radiotherapy for carcinoma of the cervix. Since these fistulae are often difficult to treat plasma fractions rich in fibrinogen clotted with thrombin are used to assist tissue adhesion. Tranexamic acid is given to prevent lysis of the fibrin plug. The fibrin forms a supporting framework for migrating fibroblasts and developing capillary buds.2'
Other inhibitors of fibrinolysis Clinical experience so far is mainly limited to two groups of fibrinolytic inhibitors, the co-aminocarboxylic acids and aprotinin. There are, however, other groups of serine protease inhibitors which may become clinically important.
The best known synthetic inhibitors of fibrinolysis are lysine; epsilon-aminocaproic acid, or 6-aminohexanoic acid;22 cyclic aminocarboxylic acid (trans-4-aminomethyl cyclohexane carboxylic acid, or AMCHA, tranexamic acid); p-aminomethyl benzoic acid (PAMBA); 4-aminomethyl-bicyclo-2,2,2-octane carboxylic acid (AMBOCH);23 and related co-aminocarboxylic acids. They all appear to inhibit plasminogen activation by tissue activator (blood activator) due to interference as a result of a displacement of plasminogen from the fibrin surface. The molecular basis is due to complementary structures in the plasminogen molecule called lysine-binding sites and Future prospects for use offibrinolysis inhibitors complementary sites in the fibrin molecule.24 25 A second well-known fibrinogen inhibitor is aprotinin, the basic protease inhibitor from bovine organs. Aprotinin has a broad inhibition specificity since it forms equimolar complexes with trypsin, chymotrypsin, plasmin, and glandular kallikreins. Their toxicity is low and with a molecular weight of 6500 antigenicity is not a problem. Unfortunately the polypeptide aprotinin has to be given intravenously. It has been used mainly in acute pancreatitis. Several Glycosaminoglycan polysulphates of bovine origin are semi-synthetic analogues of heparin which are virtually inactive in vitro. When given by parenteral injection the heparin analogue has almost the same potentiating effect on antithrombin III as heparin but considerably less on the activated partial clotting time.30 An ideal drug for preventing thrombosis would indeed inhibit the generation of factor Xa without delaying significantly the clotting time.
The future lies in finding synthetic inhibitors capable of discriminating between enzymes of closely related specificity. In view of the great number of physiologically important serine proteases continually being discovered a more precise description of the structure of their active site will hopefully enable inhibitors to be synthesised that are able to discriminate between the different serine proteases.
